NRG1 fusion

"NRG1 fusions in solid tumors." Research by @BrindaGuptaMD, @oncoOuLungCA, @benweinbergmd, @MNagasaka, @HosseinBorghaei, @PatrickCMa1, @StephenVLiu and others at #ASCO23 @LombardiCancer (@RueschCenter)

If you’re at the Developmental Therapeutics posters at #ASCO23, stop by poster 330 where Dr. Brinda Gupta is presenting our work on #NRG1 fusions in solid tumors. 153 different fusion partners!! (@StephenVLiu)

#AACR23 | Section 47 | Tuesday CT229 - CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors Jessica Lin, MD (@JessicaJLinMD) ➡️ https://t.co/XuAsTtxZKd @AACR (@MGHCancerCenter)

#CedarsSinaiCancer at #AACR23. Dr. Karen Reckamp @ReckampK is co-author on “CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 fusion positive locally advanced or metastatic solid #tumors” presented at 6:00am. @CedarsSinaiMed (@CSCancerCenter)

#PLCClive23 Dr. @Joshua_Reuss discusses #NRG1 fusions as a new target for lung cancer (and others including pancreatic). RNA-seq essential to find this fusion and outcomes with standard therapy poor but new agents are promising (including zenocutuzumab). (@StephenVLiu)

Excellent talk by @JPatelMD about rare but actionable #NTRK and #NRG1 fusions. Issue = these fusions cannot be treated unless they can be found, which often requires RNA-based testing. How can we make this testing more standard? #lcsm #TTLC23 @EGFRResisters (@ivybelkins)

In our new Publication Perspective video, based on a review, @StephenVLiu, on behalf of his co-authors, discusses the role of afatinib and other ErbB-targeting agents for NRG1 fusion-driven tumors. Watch the video: 📽️ https://t.co/5rg28nNHVM #NRG1 #NSCLC #LCSM #lungcancer (@VJofBiomedicine)

Great to see this collaborative study between @UPMCHillmanCC @JHUPath @MayoClinicPath @CLEClinicLabs. Tweetorial coming out soon, but if you are interested in Actionable Fusion Genes (FGFR2, ALK, BRAF, NRG1, RET and others) in #PancreaticCancer look to ITPNs of the #Pancreas. (@PancPathologist)

Discussing the #unicorns in targets for #lungcancer: NRG1,NTRK,and RET fusions ⁦@DDoroshow⁩ ⁦@gotoPER⁩ #winterlung chair ⁦@JulieBrahmer⁩ with ⁦@FSkoulidis⁩ #DrChristineBaik #miami challenge for medical oncologists to keep up with so much data, side effects (@donnashort)

#WLC2023 @DDoroshow @MountSinaiNYC presents The Unicorns of NSCLC #RET #NTRK #NRG1 fusions. ➡️importance of NGS (+RNA) testing to find these rare but treatable cancers. #lcsm @gotoPER @NTRKers @RetRenegades (@Latinamd)

@LuisERaez1 (@MCIStrong) explains “NTRK and NRG1 Fusion Proteins” at #LALCA23. #LCSM (@IASLC)

@JCOPO_ASCO Impact of #PrecisionOncology in #PDAC #pancreatic cancers! "Response to Seribantumab, anti-HER3 #monoclonalAb in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion" https://t.co/hBFyAJuwfz @OncoAlert @MPishvaian @pashtoonkasi (@ADesaiMD)

Case report in @JCOPO_ASCO Clinical Response to a HER-3/ERBB3 targeted Monoclonal Antibody, in a Patient With Metastatic #PancreaticCancer Harboring an NRG1 Fusion. https://t.co/Y6VKGpRn08 Younger onset PDAC (this was in a 38y old) with WT KRAS 👉🏽 Chase those fusions! (@Aiims1742)

Case @JCOPO_ASCO illustrating response to anti-HER3 mAb in #NRG1 fusion-positive pancreatic cancer. NRG1 fusions are rare, but actionable and occur across various tumor types but they are challenging to find - #RNA based NGS helps significantly. https://t.co/GY2KfSN5hO (@StephenVLiu)

@StephenVLiu, MD, sat down with Aggrego Oncology to discuss the Efficacy of #Seribantumab in Patients With Advanced #SolidTumors & an #NRG1 Gene Fusion || To watch the video & read more about the #CRESTONE study visit: https://t.co/2tCFKNW48I #medtwitter #onctwitter #trials (@AggregoOncology)

@StephenVLiu, MD, sat down with Aggrego Oncology to discuss the Efficacy of #Seribantumab in Patients With Advanced #SolidTumors & an #NRG1 Gene Fusion || To watch the video & read more about the #CRESTONE study visit: https://t.co/2tCFKNW48I #medtwitter #onctwitter #trials (@AggregoOncology)

@StephenVLiu, MD, sat down with Aggrego Oncology to discuss the Efficacy of #Seribantumab in Patients With Advanced #SolidTumors & an #NRG1 Gene Fusion || To watch the video & read more about the #CRESTONE study visit: https://t.co/2tCFKNWBYg #medtwitter #onctwitter #trials (@AggregoOncology)

@MNagasaka discusses CRESTONE: Initial Efficacy & Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions at #ACLC22. She concludes that the drug is generally well tolerated, & that it could be a new SOC for patients with solid tumors harboring NRG1 fusions. (@IASLC)

@MNagasaka presented the initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions (CRESTONE). #ACLC22 @IASLC #LCSM (@HHorinouchi)

#SolidTumor News: @StephenVLiu, MD, discusses the efficacy of seribantumab in patients with advanced solid tumors and an NRG1 gene fusion || To learn more about the CRESTONE Study, visit: https://t.co/X9rNVe2B5F #medtwitter #CRESTONEstudy #NRG1 #oncology (@AggregoOncology)

🔥Comprehensive characterization of KRAS WT #pancreaticcancer🔥 @NatureComms https://t.co/Z8m292E6Bg 👉high freq. of fusions (6-67%)>BRAF, NRG1, NTRK, FGFR2 👉R5A2, PROX1 & chr1q amplification > druggable 🎯? 👉transcriptome similar to #CCA 🧐KRAS testing in #PDAC key @myESMO (@ArndtVogel)

Dr. @JessicaJLinMD will provide the latest updates in the management of #ROS1 #RET #NTRK and #NRG1 fusion-positive lung cancer at #DCLung22 on Saturday, October 29, 2022. Get all of the latest updates in one place! Full agenda, faculty and registration at: https://t.co/rZMLIyUBL3 (@StephenVLiu)

Dr. @JessicaJLinMD will provide the latest updates in the management of #ROS1 #RET #NTRK and #NRG1 fusion-positive lung cancer at #DCLung22 on Saturday, October 29, 2022. Get all of the latest updates in one place! Full agenda, faculty and registration at: https://t.co/rZMLIyUBL3 (@StephenVLiu)

clinical trial design for patients with mNSCLC with NRG1 fusions--by @StephenVLiu of course, whose constant caring and hard work for all suffering from this lethal disease exceeds even the highest expectations https://t.co/gbr5waqYvB (@aliama)

Durable response (21+ months) to zenocutuzumab (HER2/HER3 bispecific Ab) in #NRG1 fusion positive breast cancer outlined @JCOPO_ASCO. NRG1 fusions are rare but seen across tumor types (RNA-based NGS needed to detect them) and several drugs in development. https://t.co/wrS8GgpyXL (@StephenVLiu)

Great to see this plain language summary by @StephenVLiu on #NRG1 fusions, an emerging biomarker in #lungcancer #LCSM (@acmoorephd)

@StephenVLiu leads our HER2 and HER3 session: Fresh off the flight and already giving a fantastic talk on diagnosing and targeting NRG1 fusions in lung cancer. #DAVAHawaiiLung (@OMIonc)

I fully agree. Specifically for NRG1 fusions, we need good education. RNAseq is key. Strong efforts required to identify these patients. #WCGIC2022 @myESMO @OncoAlert (@ArndtVogel)

#TumorBoardTuesday #3⃣ (I missed this in the pre-review) ✅Alison Schram🧑‍🏫a trial of zenocutuzumab, a HER2 x HER3 bispecific Ab for NRG1 fusion+ Ca 👉73 assessable Pts 👉Mostly NSCLC & PDAC ORR = 34% (42% in PDAC) Median duration of response = 9.1 months 🔎Abstract #105 (@MPishvaian)

#CedarsSinaiCancer at #ASCO22. Dr. Karen Reckamp @ReckampK is co-author on “CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions” being presented at 9:45am. @ASCO @CedarsSinaiMed @CSCancerCare (@CSCancerCare)

#ASCO22 CRESTONE phase II clinical trial in NRG1 fusion solid tumors, ORR 33% with 2 complete responses @elevationonc @Odintsov_I @LDelasos @MLadanyi (@Moranaaa)

CRESTONE: Initial efficacy and safety of seribantumab in #solidtumors harboring NRG1 fusions Join @DCarrizosaMD in S406 at 11:45 am today @elevationonc (@IDEOlogyHealth)

Happening now, @DCarrizosaMD presenting at DT oral session on CRESTONE, phI trial seribantumab in solid tumor with NRG1 gene fusions - tune in #ASCO22 @LevineCancer (@atanmdlci)

#ASCO22 Cohort 1 data here includes 15 patients (safety population = 35), primarily NSCLC and one pancreatic. Likely reflects testing practice (#NRG1 fusions much easier to find on RNA-seq due to massive intronic regions). Well tolerated (6% dose reduction, no d/c for AEs). (@StephenVLiu)

Including a 42% ORR in PDAC! I'm increasingly convinced that nothing is bringing us more authentically into the era of histology agnosticism than targetable fusions like NRG1 #pancsm #ASCO22 https://t.co/rzgaHCBnvw (@marklewismd)

The #OncoAlertTopTweet 🚨 Day 3⃣ #ASCO22 Tweet @BenjaminBesseMD NRG1 fusions are part of the #NSCLC 🫁drivers family‼️ Zenocutuzumab, a HER2-HER3 bispecific antibody, has significant activity in a NRG1+ tumor agnostic population Best, @weoncologists (@OncoAlert)

NRG1 fusions are part of the NSCLC drivers family!! Zenocutuzumab, a HER2-HER3 bispecific antibody, has significant activity in a NRG1+ tumor agnostic population (n=83), ~50% being NSCLC. ORR=34% overall and 35% in NSCLC. Median DoR 9.1 mo and favorable safety profile. #ASCO22 (@BenjaminBesseMD)

NTRK, ALK, BRAF and most of all NRG1 rearrangements/fusions in pancreatic cancer. Long list in Cholangiocarcinoma (@fedenichetti)

.@JoelNealMD, of @StanfordMed, discusses the emergence of targets such as HER2 exon 20 insertions and amplification, MET amplification, and NRG1 fusions. #lcsm https://t.co/fKVdC9CeCs (@OncLive)

#PLCClive22 Dr. @alexdrilon provides an expert overview of #NRG1 fusions - present across tumor types but also seen in NSCLC. New targeted agents showing promise. A lot of heterogeneity with these fusions - not clear how that impacts outcomes. (@StephenVLiu)

Dr. Parneet Cheema @drcheema_cancer gives an overview of #NRG1 fusions at #TTLC22. Rare but potentially actionable. Enriched in mucinous adenocarcinoma. Poor outcomes with standard therapy. Best identified with RNA-based NGS. #LCSM @IASLC (@StephenVLiu)

#TTLC22 Large track record for effectively targeting #NRG1 fusions in NSCLC with the pan-ErbB TKI afatinib. Multiple case reports published and prospective study underway. #LCSM (@StephenVLiu)